The global synthetic biology market was valued at USD 14.30 billion in 2024 and is projected to reach USD 17.09 billion in 2025. By 2032, the market is expected to grow significantly to USD 63.77 billion, registering a robust compound annual growth rate (CAGR) of 20.7% during the forecast period. In 2024, North America led the synthetic biology market, accounting for a dominant share of 52.09%.

The synthetic biology market is rapidly expanding, driven by advancements in genetic engineering, biotechnology, and computational biology. This innovative field combines principles of biology and engineering to design and construct new biological parts, devices, and systems for a wide range of applications. The market is witnessing increasing adoption across healthcare, agriculture, industrial manufacturing, and environmental sectors. Rising demand for sustainable solutions, bio-based products, and precision medicine is further fueling market growth. As research and development activities accelerate and technological capabilities improve, the synthetic biology market is expected to play a transformative role in shaping the future of biotechnology and life sciences.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/synthetic-biology-market-107168**

Market Segmentation

• By Product Type: The synthetic biology market is segmented into synthetic DNA, synthetic genes, synthetic cells, chassis organisms, and others, with synthetic DNA being the most widely used.
• By Technology: Includes gene synthesis, genome engineering, sequencing, bioinformatics, and cloning technologies. Gene synthesis and genome editing hold significant market shares in the synthetic biology market.
• By Application: Segmented into healthcare, agriculture, industrial biotechnology, environmental applications, and others. Healthcare dominates the synthetic biology market due to its use in therapeutics and diagnostics.
• By End User: Includes pharmaceutical & biotechnology companies, academic & research institutes, and healthcare providers. Pharma and biotech companies are the leading end users in the synthetic biology market.
• By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa form the regional segments of the synthetic biology market.

List Of Key Synthetic Biology Companies Profiled

• Hoffmann-La Roche Ltd(Switzerland)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc (U.S.)
• Oxford Nanopore Technologies plc. (U.K.)
• Laboratory Corporation of America Holdings (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Myriad Genetics, Inc. (U.S.)